Terms: = Leukemia AND RUNX1T1, ENSG00000079102, 862 AND Prognosis
74 results:
1. AML with RUNX1::runx1t1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
[TBL] [Abstract] [Full Text] [Related]
2. CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::runx1t1/3 fusions.
Tauziède-Espariat A; Lew-Derivry L; Abbou S; Métais A; Pierron G; Reynaud S; Masliah-Planchon J; Mariet C; Hasty L; Dangouloff-Ros V; Boddaert N; Csanyi M; Aline-Fardin A; Lamaison C; Chrétien F; Beccaria K; Puget S; Varlet P
Acta Neuropathol Commun; 2024 Jan; 12(1):12. PubMed ID: 38243303
[TBL] [Abstract] [Full Text] [Related]
3. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::runx1t1.
Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
[TBL] [Abstract] [Full Text] [Related]
4. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::runx1t1.
Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
[TBL] [Abstract] [Full Text] [Related]
5. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Shen YJ; Zhang Y; Chang J; Wang HF; Ye XN; Zhu L; Jin J; Zhu HH
Ann Hematol; 2023 Jul; 102(7):1731-1738. PubMed ID: 37145324
[TBL] [Abstract] [Full Text] [Related]
6. RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification.
Yang Y; Shu Y; Tang Y; Zhao S; Jia Y; Ji J; Ma H; Lin T; Zheng K; Xu H; Wu Y
Cancer Med; 2023 Apr; 12(8):9156-9166. PubMed ID: 36916780
[TBL] [Abstract] [Full Text] [Related]
7. Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid leukemia.
Gudipati M; Butler M; Koka R; Baer MR; Ning Y
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833323
[TBL] [Abstract] [Full Text] [Related]
8. Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia.
Mao X; Yin R; Liu L; Zhou Y; Yang C; Fang C; Jiang H; Guo Q; Tian X
Pediatr Neonatol; 2023 Jul; 64(4):435-441. PubMed ID: 36809862
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
Shiba N
Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
[TBL] [Abstract] [Full Text] [Related]
10. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY; Li JF; Zhu YM; Lin XJ; Wen LJ; Zhang F; Zhang YL; Zhao M; Fang H; Wang SY; Lin XJ; Qiao N; Yin W; Zhang JN; Dai YT; Jiang L; Sun XJ; Xu Y; Zhang TT; Chen SN; Zhu HH; Chen Z; Jin J; Wu DP; Shen Y; Chen SJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2211429119. PubMed ID: 36442087
[TBL] [Abstract] [Full Text] [Related]
11. Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the prognosis for Acute Myeloid leukemia.
Gao Y; Zhou JF; Mao JY; Jiang L; Li XP
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291567
[TBL] [Abstract] [Full Text] [Related]
12. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid leukemia.
Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
[TBL] [Abstract] [Full Text] [Related]
13. [A favorable clinical course of acute myeloid leukemia with t (6;21;8)(p23;q22;q22)].
Wada A; Doki N; Otsuka Y; Adachi H; Konuma R; Kishida Y; Konishi T; Yamada Y; Nagata A; Nagata R; Marumo A; Noguchi Y; Mukae J; Toya T; Igarashi A; Najima Y; Kobayashi T; Harada H; Harada Y; Sakamaki H; Ohashi K
Rinsho Ketsueki; 2022; 63(2):104-107. PubMed ID: 35264498
[TBL] [Abstract] [Full Text] [Related]
14. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid leukemia With RUNX1-runx1t1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract] [Full Text] [Related]
15. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
[TBL] [Abstract] [Full Text] [Related]
16. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Zhang W; Jang E
PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
[TBL] [Abstract] [Full Text] [Related]
17. runx1t1, a potential prognostic marker in breast cancer, is co-ordinately expressed with ERα, and regulated by estrogen receptor signalling in breast cancer cells.
Saikia S; Pal U; Kalita DJ; Rai AK; Sarma A; Kataki AC; Limaye AM
Mol Biol Rep; 2021 Jul; 48(7):5399-5409. PubMed ID: 34264479
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological Evaluation of Acute leukemias in a Tertiary Care Hospital: A Cross-Sectional Study.
Patel GN; Gudur R; Gudur A; Oswal RM; Kanethkar S
Turk Patoloji Derg; 2021; 37(2):145-153. PubMed ID: 33973643
[TBL] [Abstract] [Full Text] [Related]
19. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
Owen N; Minko IG; Moellmer SA; Cammann SK; Lloyd RS; McCullough AK
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836581
[TBL] [Abstract] [Full Text] [Related]
20. A new four-way complex translocation variant involving the t(8;5;21;4)(q21;q13,q22,q31) and the relocalization of AML1/ETO fusion gene.
Isik S; Uskudar Teke H; Gunden G; Erzurumluoglu Gokalp E; Cilingir O; Artan S; Durak Aras B
Cancer Genet; 2021 Aug; 256-257():1-4. PubMed ID: 33773407
[TBL] [Abstract] [Full Text] [Related]
[Next]
